HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TALC INHALATION CARCINOGENICITY ISSUE MAY NEED MORE STUDY

This article was originally published in The Rose Sheet

Executive Summary

TALC INHALATION CARCINOGENICITY ISSUE MAY NEED MORE STUDY, FDA Office of Cosmetics and Colors Acting Director John Bailey, PhD, said at a recent workshop on talc safety cosponsored by FDA and the International Society of Regulatory Toxicology and Pharmacology. "It sounds as if we're leaning in the direction of needing more studies," Bailey said, following a discussion of inhalation data on the ingredient. The workshop was held Jan. 31 and Feb. 1 at the National Institutes of Health campus in Bethesda, MD.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel